5-(甲基硫代)烟酸甲酯 | 74470-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(甲基硫代)烟酸甲酯
• 中文别名: 5-(甲硫基)烟酸甲酯
• 英文名称: methyl 5-(methylthio)nicotinate
• 英文别名: methyl 5-methylsulfanylpyridine-3-carboxylate
• CAS: 74470-43-2
• 化学式: C₈H₉NO₂S
• 分子量: 183.231
• InChiKey: MCBPMUHKVUPWEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-(甲基硫代)烟酸甲酯 在 甲醇 、 氯 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 5-(氯磺酰基)烟酸甲酯
  参考文献：
  名称：

  Nicotinyl aspartyl ketones as inhibitors of caspase-3

  摘要：

  Caspase-3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. Since P, aspartic acid is a required element of recognition for this enzyme, a library of capped aspartyl aldehydes was synthesized using solid-phase chemistry. The 5-bromonicotinamide derivative of the aspartic acid aldehyde was identified to be an inhibitor of caspase-3. Substitution at the 5-position of the pyridine ring and conversion of the aldehyde to ketones led to a series of potent inhibitors of caspase-3. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00390-1
• 作为产物：
  描述：

  5-溴烟酸 在 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-(甲基硫代)烟酸甲酯
  参考文献：
  名称：

  Nicotinyl aspartyl ketones as inhibitors of caspase-3

  摘要：

  Caspase-3 is a cysteinyl protease that mediates apoptotic cell death. Its inhibition may have an important impact in the treatment of several degenerative diseases. Since P, aspartic acid is a required element of recognition for this enzyme, a library of capped aspartyl aldehydes was synthesized using solid-phase chemistry. The 5-bromonicotinamide derivative of the aspartic acid aldehyde was identified to be an inhibitor of caspase-3. Substitution at the 5-position of the pyridine ring and conversion of the aldehyde to ketones led to a series of potent inhibitors of caspase-3. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00390-1

文献信息

• [EN] SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES<br/>[FR] PYRIDAZINONE SUBSTITUÉE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE MALADIES NEUROMUSCULAIRES
  申请人：EDGEWISE THERAPEUTICS INC

  公开号：WO2021231615A1

  公开（公告）日：2021-11-18

  Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

  本文披露了用于治疗神经肌肉疾病，如杜欣氏肌肉萎缩症（DMD）的吡啶并嗪酮化合物、结合物和药物组合物。所披露的化合物在治疗DMD和调节炎症抑制剂IL-1、IL-6或TNF-α等方面具有用途。
• SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS
  申请人：NGUYEN Duy

  公开号：US20090186911A1

  公开（公告）日：2009-07-23

  The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.

  本发明涉及公式（I）的磺氧胺取代的喹唑啉衍生物，其制备方法以及作为治疗各种疾病的药物的用途。
• Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments
  申请人：Bayer Schering Pharma AG

  公开号：US07863283B2

  公开（公告）日：2011-01-04

  The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.

  本发明涉及式(I)的硫代氧胺取代的喹噁啉衍生物，其制备过程以及它们作为治疗各种疾病的药物的用途。
• Pyridazinone compounds and uses thereof
  申请人：Edgewise Therapeutics, Inc.

  公开号：US11091464B2

  公开（公告）日：2021-08-17

  Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

  本文公开了用于治疗神经肌肉疾病（如杜氏肌肉萎缩症（DMD））的取代哒嗪酮化合物、共轭物和药物组合物。所公开的化合物除其他外，可用于治疗 DMD 和调节炎症抑制剂 IL-1、IL-6 或 TNF-α。
• WO2020097266A5
  申请人：——

  公开号：WO2020097266A5

  公开（公告）日：2022-05-17